Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lyka Labs's Enterprise Value is ₹2,702 Mil.
Lyka Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Lyka Labs's EV-to-FCF for today is .
The historical rank and industry rank for Lyka Labs's EV-to-FCF or its related term are showing as below:
BOM:500259'
s EV-to-FCF Range Over the Past 10 Years
Min: -45.89 Med: 0 Max: 0
Current: -45.89
BOM:500259's EV-to-FCF is ranked worse than 100% of 343
companies
in the Biotechnology industry
Industry Median: 14.79
vs BOM:500259: -45.89
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lyka Labs's share price for today is ₹63.57.
Lyka Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-2.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lyka Labs EV-to-FCF Related Terms
Lyka Labs EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Lyka Labs's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500259 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Lyka Labs's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lyka Labs's EV-to-FCF falls into.
Lyka Labs's current Enterprise Value is ₹2,702 Mil.
Lyka Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹63.57 is trading 50.2% below its estimated GF Value™ of ₹127.54.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
EV-to-FCF:
GF Value™: ₹127.54 vs. price of ₹63.57 (50.2% below fair value)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
51GF Score
Get the complete analysis for BOM:500259
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
